Isomorphic Labs Valued at 50 Billion Dollars After New Funding, Bloomberg Reports

Isomorphic Labs secured five billion dollars in a Series C financing round, positioning the artificial intelligence drug discovery startup at a valuation of roughly 50 billion dollars according to a Bloomberg report cited by FAZ.

Greenoaks and Sequoia Capital led the oversubscribed round, joined by new investor Andreessen Horowitz alongside returning backers including Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund, Dr, according to Dr. Web. Web reported.

The London-based company, founded in 2021 as a spinout from Google parent Alphabet, employs roughly 500 people and plans to use the capital to build out its IsoDDE platform and prepare for human testing, according to Dr. Web.

“As we founded Isomorphic, we were convinced that biology could be understood and modeled at the most fundamental molecular level and radically accelerated by AI,” Demis Hassabis, founder and chief executive officer of Isomorphic Labs, told FAZ.

Rapid capital accumulation

The latest transaction follows a series of substantial funding injections gathered over short intervals. Bloomberg reported that the startup took in 600 million dollars in March 2025 before Thrive Capital led a 2.1 billion dollar Series B round in May 2026, bringing total funding to approximately 7.7 billion dollars across the rounds, Dr. Web reported.

Isomorphic Labs holt 5 Mrd. Dollar für KI-Medikamente
Photo: drweb.de

The incoming capital outpaces the annual research budgets maintained by many established pharmaceutical corporations. Isomorphic Labs maintains operations in London, Boston, and Lausanne, according to FAZ.

While the firm has not officially confirmed the reported 50 billion dollar valuation, FAZ said that the figure places the startup far ahead of other European artificial intelligence ventures.

Isomorphic Labs advances 20 drug programs toward preclinical trials

Isomorphic Labs aims to design drug candidates digitally and predict their properties before physical laboratory testing. Hassabis said that the company’s platform “generates molecules with unprecedented precision and speed,” according to FAZ.

The startup is currently working on roughly 20 programs targeting cancer, immune system conditions, and inflammatory diseases. An oncology project is approaching preclinical trials, and the firm has already established partnerships with pharmaceutical companies including Eli Lilly, Johnson & Johnson, and Novartis, FAZ reported.

Despite the rapid progress, no artificial intelligence-designed medication has yet received approval from a regulatory drug agency. The start of the company’s first clinical trials remains unconfirmed by a specific date.

Industry skepticism

Skeptics within the pharmaceutical sector have cautioned against overestimating current artificial intelligence capabilities. Dave Ricks, chief executive officer of Eli Lilly, told FAZ that large language models exhibit limited utility in biology and chemistry beyond protein structure prediction.

Jeff Leiden, executive chairman of Vertex Pharmaceuticals, told FAZ that his firm tested technology from roughly 50 artificial intelligence companies across a dataset of 10,000 compounds without producing a functional drug candidate.

“Claims by AI optimists that computer-designed medicines could cure most diseases in a few years are completely overblown,” Leiden told FAZ, describing artificial intelligence as a useful copilot for researchers rather than a standalone cure generator.

Christian Diehl, a research manager at Novartis, also questioned projections that AI design could produce new medications within weeks by 2030, though he acknowledged the rapid pace of technological development, FAZ reported.

Isomorphic Labs traces its origins to DeepMind’s AlphaFold 2 breakthrough in protein structure prediction, which inspired founder Demis Hassabis to establish the company as an Alphabet spin-off in February 2021 before its public announcement that November.

The venture has since expanded beyond AlphaFold, developing its proprietary IsoDDE platform across multiple drug modalities and releasing AlphaFold 3 in May 2024, a model trained on roughly 100,000 protein structures that has since mapped over 200 million proteins for more than 3.3 million researchers worldwide.

After opening a second office in Lausanne in December 2022, Isomorphic Labs formed drug discovery partnerships with Novartis and Eli Lilly in January 2024, extended the Novartis agreement in February 2025, and added a Johnson & Johnson collaboration in January 2026.

The company appointed Dr. Ben B. Wolf as chief medical officer and opened a Cambridge, Massachusetts office in June 2025, then named former chief AI officer Max Jaderberg as president in January 2026, advancing toward its goal of first-in-human clinical trials.

The company has not confirmed when its initial human clinical trials will officially begin.

Newsroom

Newsroom at Archysport.